Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Pharma & Bio
Lifestyle

Cholera Vaccine ‘Shortage’ Leads to Mass Vaccination Campaign… EuBiologics Co., Ltd. Sees ‘Boom in Orders’

EuBiologics Co., Ltd.(206650)is emerging as a direct beneficiary of growing global demand for cholera vaccines. Since 97.3% of the company’s revenue comes from cholera vaccines, changes in global dema…
  • 2026-09-21 08:46:02
  • KIM JI-WAN
Technology

ORM-6151 Stalled Due to BMS’s Strategic Realignment… Upcoming New Drug Following Orum AML Faces Test of Its Differentiation

Bristol-Myers Squibb (BMS) has halted development of “ORM-6151” (BMS project name BMS-986497), a treatment for acute myeloid leukemia (AML), which it acquired from #Orum Therapeutics, Inc. for an upfr…
  • 2026-09-21 08:32:02
  • NA EUN-KYUNG
Technology

'Tactile Display' Dot Expands Collaboration with Google Gemini... Targeting the Visual Rehabilitation Market

Dot, a social venture that commercialized the world’s first tactile display, is breaking free from the label of “manufacturer of assistive devices for the visually impaired.” The company is expanding …
  • 2026-09-21 08:16:02
  • Kim Seung-kwon
Technology

[K-Bio’s Expansion into Japan] (2) Same Japan, Different Formula for Success… Celltrion’s Anticancer Drugs Also Rank “No. 1”

Celltrion(068270), which has reclaimed the top spot in Japan’s infliximab market for the first time in about 11 years, has created yet another formula for success in the anti-cancer biosimilar market.…
  • 2026-09-21 08:02:03
  • KIM SAE-MI
Technology

[K-Bio’s Expansion into Japan] (1) Trust Over Low Prices… Remsima Tops the Charts in Japan 11 Years After Entry

Celltrion(068270) Celltrion’s flagship biosimilar, “Remsima,” has surpassed the original drug to become the top-prescribed medication in Japan. While Remsima has rapidly expanded its market presence, …
  • 2026-09-21 08:02:02
  • KIM SAE-MI
Lifestyle

ABL Bio Inc. Facing Allegations of Unfair Trading: The Key Question Is Whether the CEO Was Involved… Is a Trading Suspension Possible?

ABL Bio Inc.(298380) As news spreads that CEO Lee Sang-hoon’s family is also implicated in allegations of trading based on insider information, anxiety is growing among shareholders who invested in AB…
  • 2026-09-21 08:01:04
  • Kim Jinsoo
Technology

QuantaMatrix Incorporated Becomes ‘Qumico’… What Is the ‘Two-Track Synergy’ Strategy Developed with MiCo Ltd.?

(Graphic: ChatGPT) QuantaMatrix Incorporated(317690)is expanding its collaboration with MiCo Ltd. under the new brand name “QMiCo.” This two-track strategy involves growing “dRAST,” a rapid antibi…
  • 2026-09-21 08:01:03
  • Minji Son
Lifestyle

Why HANS BIOMED CORPORATION Is Increasing Its Stake in A-Tems… The Value of ‘A-Paste-C’

HANS BIOMED CORPORATION(042520)is expanding its stake in its affiliate, A-Tems, with the aim of maximizing investment returns on A-Tems’ core pipeline. Given that A-Tems possesses technology and exper…
  • 2026-09-21 07:31:02
  • Kim Jinsoo
Technology

Opacalim Clinical Trials Paused… A Closer Look at the Preconditions for SK BIOPHARMACEUTICALS’s 2.3 Trillion Won Deal

SK BIOPHARMACEUTICALS(326030)has drawn attention by repeatedly emphasizing that the deal to acquire “Opacalym” (BHV-7000), a new drug candidate for epilepsy, from the U.S. biotech company Biohaven is …
  • 2026-09-19 08:41:01
  • KIM SUNG-JIN
Technology

SK BIOPHARMACEUTICALS’ Cenobamate: How Far Will ‘Supply Expansion’ Go? Impact of Increased Prescriptions in the U.S.?

(Graphic: ChatGPT) SK BIOPHARMACEUTICALS(326030)The value of internal supply contracts for “cenobamate” (brand name Xcopri), an epilepsy treatment supplied by SK Life Science to its U.S. subsidiar…
  • 2026-09-19 08:21:02
  • Minji Son
prev 21 22 23 24 25 26 27 28 29 30 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English